Clinical Trials

    Showing 1 - 4 of 4 Prostate Cancers

    Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)

    Status: Enrolling

    Investigator: Patrick Prath

    Study Coordinator: Syeda Sarwat

    Phone: 832.358.4365

    This is an international multi-centre, open-label, randomized phase III trial comparing Docetaxel chemotherapy added to standard of care Androgen Deprivation Therapy (ADT) + Androgen-Receptor Pathway Inhibitor (ARPI) versus standard of care Androgen ... Read more >

    Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm (ARASEC)

    Status: Open Not Enrolling

    Investigator: Jian Guan

    Study Coordinator: Nicole Barrios

    Phone: 713.441.5607

    This is a phase 2 open label single arm study using an external control arm, to assess if the addition of darolutamide to ADT provides superior efficacy in terms of progression-free survival (PFS), as compared to ADT alone for men diagnosed with meta... Read more >

    Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Status: Open Not Enrolling

    Investigator: Patrick Prath

    Study Coordinator: Johnnie Young

    Phone: 346.238.5839

    The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.... Read more >

    Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

    Status: Open Not Enrolling

    Investigator: Jian Guan

    Study Coordinator: Johnnie Young

    Phone: 346.238.5839

    This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.... Read more >